ArticleFrontiers in cellular and infection microbiology2017
Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review.BMC infectious diseases · 2020Pooled it
- Efficacy and safety of colistin monotherapy versus colistin-based combination therapy in pediatric patients with multidrug-resistant gram-negative infections: A propensity score analysis.New microbes and new infections · 2026Article
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- Genes and physiological strategies in bacterial antibiotic resistance.Frontiers in microbiology · 2026Review
- In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Predicting infections with multidrug-resistant organisms (MDROs) in neurocritical care patients with hospital-acquired pneumonia (HAP): development of a novel multivariate prediction model.Microbiology spectrum · 2025Article
- Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin.PLoS pathogens · 2024Article
- In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates.European journal of medical research · 2024Article
- Enhanced Efficacy of Ciprofloxacin and Tobramycin againstAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Prevalence of Carbapenemases in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Antibacterial and Antibiofilm Properties of the Alexidine Dihydrochloride (MMV396785) againstAntibiotics (Basel, Switzerland) · 2023Article
- Revealing the dynamic landscape of drug-drug interactions through network analysis.Frontiers in pharmacology · 2023Article
- Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study.Infection and drug resistance · 2023Article
- Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.Microbiology spectrum · 2022Article
- Anti-Iranian journal of basic medical sciences · 2022Article
- Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-ResistantPharmaceutics · 2022Article
- Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-ResistantJournal of clinical medicine · 2022Review
- Antimicrobial Activity of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) against Clinical Isolates of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Synergistic Effect of Lithocholic Acid with Gentamicin against Gram-Positive Bacteria but Not against Gram-Negative Bacteria.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worldwide increase in the emergence of carbapenem resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.